Bone metastases are common in advanced cancers including prostate adenocarcinoma, where there is evidence of bone metastases in more than 70% of patients with advanced disease. Despite their prevalence and the important clinical implications, there is currently no widely accepted quantitative imaging assessment for response to therapy. Assessment of response or progression is typically made based on visual interpretation of bone scintigraphy in conjunction with CT and serum markers. The goal of this project is thus to develop, validate, and advance to clinical practice multi-modality quantitative metrics for assessing response of bone metastases to therapy. Combined SPECT-CT systems and the implementation of robust compensation methods has enabled the development of quantitative SPECT imaging methods, which have recently become clinically available. Here we propose to exploit the nexus of these developments via the following 3 aims. (1) Using simulation and phantom studies, we will first optimize and evaluate methods for quantitative SPECT/CT (QSPECT) imaging of Tc-99m MDP. We propose to expand the phantom studies to a QIN cooperative project in order to evaluate the methods across different scanners and centers. (2) Based on these QSPECT methods, we will develop, optimize, and characterize quantitative bone SPECT indices for assessing response to therapy. Computing these indices will involve semi-automatic segmentation of bone and bone lesions, implemented in an integrated software tool. The indices calculated will include the number of lesions, bone lesion burden, and change in lesion uptake with therapy. We will characterize the variability of the indices using realistic simulations and in pre-therapy test-retest studies. (3) Finally, we will apply the methods and validate them in current clinical trials of new therapeutic regimens for bone metastatic castrate-resistant prostate cancer. In these studies, we will evaluate the methods in terms of time to progression and will compare the methods in vivo to similar quantitative metrics estimated from Na18F PET/CT. We will also investigate the amount of additional information provided by whole-body MRI and PSMA PET/CT. We will make the methods and images available to the QIN and propose to organize challenges of segmentation and response metrics to take advantage of the QIN-wide interest in these areas. Together, these quantitative imaging tools and studies will provide a validated approach for quantitative imaging-based evaluation of response in bone metastases that is readily clinically implementable with only a minor increase in cost relative to clinical standard bone scintigraphy.

Public Health Relevance

The spread of cancer to bones is an important area of cancer research, and there are currently no widely- used quantitative imaging methods for evaluating the response to therapy in metastatic bone lesions, complicating the evaluation of new therapies. This project seeks to develop, validate, and translate into clinical practice quantitative imaging methods based on relatively easily implemented changes to bone scintigraphy protocols, the current standard of care for evaluating bone metastases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01CA140204-06A1
Application #
9446157
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Tata, Darayash B
Project Start
2011-09-19
Project End
2023-06-30
Budget Start
2018-07-17
Budget End
2019-06-30
Support Year
6
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Jacobs, Michael A; Macura, Katarzyna J; Zaheer, Atif et al. (2018) Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. Acad Radiol 25:1405-1414
Malyarenko, Dariya; Fedorov, Andriy; Bell, Laura et al. (2018) Toward uniform implementation of parametric map Digital Imaging and Communication in Medicine standard in multisite quantitative diffusion imaging studies. J Med Imaging (Bellingham) 5:011006
Newitt, David C; Malyarenko, Dariya; Chenevert, Thomas L et al. (2018) Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. J Med Imaging (Bellingham) 5:011003
Jha, Abhinav K; Mena, Esther; Caffo, Brian et al. (2017) Practical no-gold-standard evaluation framework for quantitative imaging methods: application to lesion segmentation in positron emission tomography. J Med Imaging (Bellingham) 4:011011
Lodge, Martin A (2017) Repeatability of SUV in Oncologic 18F-FDG PET. J Nucl Med 58:523-532
Lodge, Martin A; Holdhoff, Matthias; Leal, Jeffrey P et al. (2017) Repeatability of (18)F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma. J Nucl Med 58:393-398
Mena, Esther; Taghipour, Mehdi; Sheikhbahaei, Sara et al. (2017) Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma. Clin Nucl Med 42:e227-e234
Vicente, Esther M; Lodge, Martin A; Rowe, Steven P et al. (2017) Simplifying volumes-of-interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole-organ VOIs. Med Phys 44:1707-1717
Parekh, Vishwa S; Jacobs, Michael A (2017) Integrated radiomic framework for breast cancer and tumor biology using advanced machine learning and multiparametric MRI. NPJ Breast Cancer 3:43
Crandall, John P; Tahari, Abdel K; Juergens, Rosalyn A et al. (2017) A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC. EJNMMI Res 7:8

Showing the most recent 10 out of 60 publications